natgillin/translations-raw huggingface dataset:
In patients treated with myeloablative therapy followed by bone marrow transplantation The recommended starting dose of filgrastim is 1.0 MU/kg/day (10 micrograms/kg/day). 
Preporučena početna doza filgrastima je 1,0 MU/kg/dan (10 mikrograma/kg/dan).
NAME OF THE MEDICINAL PRODUCT Accofil 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe 
Accofil 30 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki
Aortitis 
Imunogenost
NAME OF THE MEDICINAL PRODUCT Accofil 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe 
Accofil 48 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki
Chest paina Astheniaa Paina 
• bol u prsnom košu
Leukocytosisa Splenic rupturea Sickle cell anaemia with crisis 
Poremećaji krvi i limfnog sustava trombocitopen ija anemijae splenomegali jaa smanjena razina hemoglobinae leukocitoza ruptura slezenea anemija srpastih stanica s krizom
Filgrastim for PBPC mobilisation after myelosuppressive chemotherapy Filgrastim should be given by subcutaneous injection. 
Filgrastim je potrebno primijeniti supkutanom injekcijom.
Filgrastim for PBPCs for mobilisation in normal donors prior to allogeneic PBPC transplantation Filgrastim should be given by subcutaneous injection. 
Filgrastim za mobilizaciju stanica preteča periferne krvi u zdravih darivatelja prije transplantacije alogenih stanica preteča periferne krvi
Uncommon side effects (seen in more than 1 in 1000 people taking Accofil): 
Manje česte nuspojave (javljaju se u više od 1 na 1000 osoba koje primaju Accofil)
• changes in blood chemistry 
• promjene rezultata krvnih pretraga • transfuzijska reakcija
The frequency is estimated as uncommon from clinical trial data. 
Na temelju podataka iz kliničkih ispitivanja, učestalost se procjenjuje kao manje česta.
Diarrhoeaa,e Vomitinga,e Nauseaa 
Učinak kemoterapije na eritrocite i trombocite
Decreased Appetitee Blood lactate dehydrogenase increased 
Poremećaji metabolizm a i prehrane smanjen apetita povišena laktat dehidrogenaz a u krvi hiperuricemija povišena mokraćna kiselina u krvi smanjena glukoza u krvi pseudogihta
Not know n itis 
Nepozna to periferni edem e
Fluid volume disturbance s 
poremećaji volumena tekućine
Cases of splenomegaly have been reported commonly following administration of filgrastim. 
Nakon primjene filgrastima često su prijavljeni slučajevi splenomegalije.
OTHER 
FR
• bone density decreased 
• smanjenje gustoće kostiju
Filgrastim for PBPC mobilisation when used alone: 
Filgrastim za mobilizaciju stanica preteča periferne krvi, kada se primjenjuje sam
Oedema peripherale 
Prijavljivanje nuspojava
(Chondrocalcino sis 
(hondrokalcino za pirofosfat)
Musculoskeletal painc 
• glavobolja • proljev
NAME OF THE MEDICINAL PRODUCT Accofil 30 MU/0.5 ml solution for injection/infusion filgrastim 
Accofil 30 MU/0,5 ml otopina za injekciju ili infuziju filgrastim s.c./i.v.
For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation 
Za mobilizaciju stanica preteča periferne krvi u zdravih darivatelja prije transplantacije alogenih stanica preteča periferne krvi
Paraesthesia 
Sljedivost
Thrombocytopenia has been reported very commonly in patients receiving filgrastim .Platelet counts should therefore be monitored closely. 
Trombocitopenija je vrlo često zabilježena u bolesnika koji primaju filgrastim.
The recommended starting dose is 1.2 MU (12 µg)/kg/day as a single dose or in divided doses. 
Preporučena početna doza je 0,5 MU (5 µg)/kg/dan primijenjena u jednoj ili više doza.
Injection site reaction 
Opći bol u prsištua reakcija na
ATCvet code: QI06AH10. 
ATCvet kod: QI06AH10.
Do not use in pregnant animals. 
Ne koristiti na gravidnim životinjama.
Shelf life of the veterinary medicinal product as packaged for sale: 18 months. 
Rok valjanosti veterinarsko-medicinskog proizvoda zapakiranog za prodaju: 18 mjeseci.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu su dostupne na web stranici Europske Agencije za lijekove (http://www.ema.europa.eu/).
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. 
Ukoliko zamijetite ozbiljne nuspojave ili druge nuspojave koje nisu opisane u uputi o VMP, molimo da se javite veterinaru.
EU/2/04/048/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/048/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml) 
EU/2/04/048/001 Liofilizat (10 bočica s po 1 dozom) + otapalo (10 bočica od 1 ml) EU/2/04/048/002 Liofilizat (50 bočica s po 1 dozom) + otapalo (50 bočica od 1 ml)
EXP (mm/yyyy) Once reconstituted use immediately. 
EXP (mm/gggg) Nakon rekonstitucije odmah primijeniti.
Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs, - against leukaemia to prevent persistent viraemia and clinical signs of the related disease. 
Aktivna imunizacija mačaka starijih od 8 tjedana: - protiv virusnog rinotraheitisa mačaka za smanjenje kliničkih znakova, - protiv infekcije kalicivirusom za smanjenje kliničkih znakova, - protiv panleukopenije mačaka za sprječavanje smrtnosti i kliničkih znakova, - protiv leukemije mačaka za sprječavanje viremije i kliničkih znakova bolesti.
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccine against rabies. 
Podaci o neškodljivosti i djelotvornosti su dostupni, što je dokaz da ovo cjepivo smije biti primijenjeno istog dana, ali ne pomiješano s Merialovim cjepivom protiv bjesnoće.
Shelf life after reconstitution according to directions: use immediately. 
Rok valjanosti nakon rekonstitucije prema uputi: primijeniti odmah.
No effect other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days. 
Nisu primijećene nikakve druge nuspojave osim onih spomenutih u odjeljku 4.6 “Nuspojave”, osim hipertermije koja iznimno može trajati 5 dana.
Primary vaccination course: - first injection: from 8 weeks of age; - second injection: 3 to 4 weeks later. 
Prvo cijepljenje: - prva injekcija: od 8. tjedna starosti; - druga injekcija: 3 do 4 tjedna kasnije.
Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the feline leukaemia component and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components. 
Revakcinacija: - prva revakcinacija mora se provesti za sve komponente jednu godinu nakon prvog cijepljenja, - naknadne revakcinacije moraju biti provedene: svake godine za komponentu leukemije mačaka i u intervalima od najviše tri godine za komponente rinotraheitisa, kaliciviroze i panleukopenije.
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product. 
Ne miješati s bilo kojim drugim veterinarsko-medicinskim proizvodom, osim otapalom priloženim za primjenu s proizvodom.
Per dose of 1 ml: Lyophilisate: 
Svaka doza od 1 ml sadrži: Liofilizat:
A local reaction may occur (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most. 
Može se javiti i lokalna reakcija (lagana bol pri palpaciji , svrbež ili ograničen otok) koja nestaje za najviše 1 ili 2 tjedna.
Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate 
Dinatrijev fosfatdihidrat Magnezijev kloridheksahidrat Kalcijev kloriddihidrat
No effect other than those already mentioned in section on “Adverse reactions” have been observed after the administration of several doses, except hyperthermia that may exceptionally last 5 days. 
Nisu primijećene nikakve druge nuspojave osim onih spomenutih u odjeljku “Nuspojave” nakon primjene nekoliko doza te hipertermije koja iznimno može trajati 5 dana.
Casein hydrolysate Collagen hydrolysate Dipotassium phosphate Potassium dihydrogen phosphate Potassium hydroxide Sodium chloride 
Kazein hidrolizat Kolagen hidrolizat Dikalijev fosfat Kalijev dihidrogenfosfat Kalijev hidroksid Natrijev klorid Dinatrijev hidrogenortofosfat Monokalijev fosfatanhidrid Kalijev klorid
The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination. 
Proizvod ima učinak smanjenja ekskrecije mačjeg kalicivirusa na početku imunosti i tijekom godine dana nakon vakcinacije.
The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the feline leukaemia component. 
Trajnost imuniteta nakon zadnje re-vakcinacije je 3 godine za komponente rinotraheitisa, kaliciviroze i panleukopenije i 1 godinu za komponentu leukemije mačaka.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9-12 weeks of age borne from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age. 
Kada se očekuje prisutnost visoke razine majčinih antitijela protiv komponenti rinotraheitisa, kaliciviroze ili panleukopenije (npr. kod mačića u dobi od 9-12 tjedana od mačaka koje su bile cijepljene prije graviditeta i/ili su prethodno bile izložene ili se sumnja da su bile izložene patogenima), prvo cijepljenje treba odgoditi do dobi od 12 tjedana.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Solvent bottle 
OSNOVNI DJELOVI NAPISANI NA MALIM JEDINICAMA UNUTARNJIH PAKOVANJA
Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule: 
Nakon rekonstitucije liofilizata s otapalom, injicirajte supkutano jednu dozu (1 ml) cjepiva, prema sljedećem rasporedu cijepljenja:
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. 
Pokazalo se da imunitet nastupa 1 tjedan nakon prvog cijepljenja protiv komponenti rinotraheitisa, kalicivirusa i panleukopenije, i 2 tjedna nakon prvog cijepljenja protiv komponente leukemije mačaka.
Lyophilisate (10x1 dose) + solvent (10x1 ml) Lyophilisate (50x1 dose) + solvent (50x1 ml) 
Liofilizat (50 x 1 doza) + otapalo (50 x 1 ml).
Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus. 
Potiče aktivni imunitet protiv virusnog rinotraheitisa mačaka, kaliciviroze mačaka, virusa panleukopenije i virusa leukemije mačaka.
Type I glass bottle containing 1 dose of lyophilisate and type I glass bottle containing 1 ml solvent, both closed with a butyl elastomer closure and sealed with an aluminium cap. 
I staklena bočica s 1 ml otapala, obje zatvorene gumenim čepom i aluminijskom kapicom.
Pack containing 10 bottles of 1 dose of lyophilisate and 10 bottles of 1 ml of solvent. 
Pakovanje sadrži 10 bočica s 1 dozom liofilizata i 10 bočica s 1ml otapala.
Gentamicin, at most .......................................................................................................................... 23 µg Solvent: 
Gentamicin, najviše .......................................................................................................................... 23 µg Otapalo:
FeLV recombinant canarypox virus (vCP97)................................................................... ≥ 107.2 CCID50. 
FeLV rekombiniran s virusom boginja kanarinca (vCP97) ............................................... ≥ 107,2 CCID50
Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent. 
Pakovanje sadrži 50 bočica s 1 dozom liofilizata i 50 bočica sa po 1ml otapala.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate bottle 
OSNOVNI DJELOVI NAPISANI NA MALIM JEDINICAMA UNUTARNJIH PAKOVANJA Bočica s liofilizatom
Per dose of 1 ml: FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50 
Svaka doza od 1ml sadrži: FHV (soj F2) ...................................................................................................................... ≥ 104,9 CCID50
PACKAGE LEAFLET FOR: Purevax RCP FeLV lyophilisate and solvent for suspension for injection 
UPUTA O VMP: Purevax RCP FeLV liofilizat i otapalo za suspenziju za injekcije.
FeLV recombinant canarypox virus (vCP97) ................................................................. ≥ 10 7.2 CCID501 1 cell culture infective dose 50%. 
FeLV rekombinantni virus boginja kanarinca (vCP97) ................................................. ≥ 10 7,2 CCID501 1 količina virusa koja zarazi 50% stanica kulture u koju je dodan virus.
Gentamicin, at most .......................................................................................................................... 23 µg 
Gentamicin, najviše .......................................................................................................................... 23 µg
Purevax RCP FeLV Lyophilisate and solvent for suspension for injection. 
Purevax RCP FeLV liofilizat i otapalo za suspenziju za injekcije.
Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia. 
Cjepivo protiv virusnog rinotraheitisa mačaka, kaliciviroze mačaka i panleukopenije i leukemije mačaka.
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501 
Inaktivirani antigenikalicivirus mačaka (soj FCV 431 i G1) .......................................... ≥ 2,0 ELISA U.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČBIOLOŠKI DJELATNIH TVARI I NOSITELJ
How often will you be given HALAVEN? 
Koliko često ćete dobivati HALAVEN?
Your doctor will determine how many cycles of treatment you should receive. 
Liječnik će odrediti koliko ciklusa terapije morate primiti.
Includes Grade 5 events. 
Uključuje događaje 5. stupnja.
Rare or not known 
Rijetko ili nepoznato
Any Grade 3 or 4 in the previous cycle 
Svaka nuspojava 3. ili 4. stupnja u prethodnom ciklusu
PROBABILITY OF SURVIVAL 
VJEROJATNOST PREŽIVLJENJA
The use of gloves, goggles, and protective clothing is recommended. 
Preporuča se uporaba rukavica, zaštitnih naočala i zaštitne odjeće.
Date of latest renewal: 19 November 2015 
Datum posljednje obnove odobrenja: 19. studenog 2015.
Creatinine clearance was estimated with the Cockcroft-Gault formula. 
Klirens kreatinina procijenjen je pomoću Cockcroft-Gaultove formule.
If you experience any of the following serious symptoms, stop taking HALAVEN and seek medical attention straightaway: 
Ako osjetite bilo koji od sljedećih ozbiljnih simptoma, prekinite uzimanje lijeka HALAVEN i odmah potražite liječničku pomoć:
What HALAVEN is and what it is used for 
Što je HALAVEN i za što se koristi
The doctor may also then decide to reduce the dose you are given. 
Liječnik može odlučiti i da Vam smanji dozu koju primate.
HALAVEN is usually given on Days 1 and 8 of every 21-day cycle. 
HALAVEN se obično daje 1. i 8. dana svakog 21-dnevnog ciklusa.
This result was confirmed with an updated overall survival analysis carried out at 77% of events. 
Ovaj je rezultat potvrđen kasnijom analizom ukupnog preživljenja u 77% događaja.
HALAVEN 71 Dacarbazine 
HALAVEN 71 Dakarbazin
Time (months) NUMBER OF PATIENTS AT RISK: 
Vrijeme (mjeseci) BROJ BOLESNIKA POD RIZIKOM:
Number of Events 
Broj događaja
The frequency of this condition is not known but it can be life-threatening. 
Učestalost ovog stanja je nepoznata, ali ono može ugroziti život.
What HALAVEN looks like and contents of the pack 
Kako HALAVEN izgleda i sadržaj pakiranja
These may be signs of a condition called sepsis - a severe and serious reaction to an infection. 
To mogu biti znakovi stanja koje se naziva sepsa, a ona je teška i ozbiljna reakcija na infekciju.
If any of these affects you, tell your doctor who may wish to stop treatment or reduce the dose. 
Ako imate nešto od navedenog, obavijestite o tome svog liječnika, koji će možda htjeti prekinuti liječenje ili smanjiti dozu.
Effects of eribulin on the pharmacokinetics of other medicines 
Učinci eribulina na farmakokinetiku drugih lijekova
Depending on the results of your blood tests, the doctor may need to delay administration of the medicine until the blood tests return to normal. 
Ovisno o Vašoj krvnoj slici, liječnik će možda morati odgoditi primjenu lijeka dok se vrijednosti krvne slike ne vrate na normalu.
What HALAVEN contains 
Što HALAVEN sadrži
Antiemetic prophylaxis including corticosteroids should be considered. 
Potrebno je razmotriti primjenu antiemetičke profilakse uključujući kortikosteroide.
TIME (months) NUMBER OF PATIENTS AT RISK HALAVEN 554 530 505 464 423 378 349 320 268243214193173151133119 99 77 52 38 32 26 22 15 13 9 7 2 2 0 Capecitabine 548 513 466 426 391 352 308 277 242214191175155135122108 81 62 42 33 27 23 17 13 12 10 2 2 1 0 
VRIJEME (mjeseci) BROJ BOLESNIKA POD RIZIKOM HALAVEN 554 530 505 464 423 378 349 320 268243214193173151133119 99 77 52 38 32 26 22 15 13 9 7 2 2 0 Kapecitabin 548 513 466 426 391 352 308 277 242214191175155135122108 81 62 42 33 27 23 17 13 12 10 2 2 1 0
The safety and efficacy of HALAVEN in children from birth to 18 years of age have not yet been established in soft tissue sarcoma. 
Sigurnost i djelotvornost lijeka HALAVEN u djece u dobi od rođenja do 18 godina još nisu ustanovljene kod sarkoma mekog tkiva.
There was no significant difference in progression-free survival or overall response rate between the treatment arms in the overall population. 
Nije bilo značajne razlike u preživljenju bez progresije bolesti ili ukupnoj stopi odgovora između te dvije terapijske skupine u cjelokupnoj populaciji.
In the pivotal trials, the corresponding publications and in some other regions e.g. the United States and Switzerland, the recommended dose is based on the salt form (eribulin mesilate). 
U ključnim ispitivanjima, radovima objavljenima na temelju tih ispitivanja i u nekim drugim zemljama, npr. Sjedinjenim Američkim Državama i Švicarskoj, preporučena doza temelji se na eribulinu u obliku soli (eribulinmesilat).
HALAVEN will be given to you by a doctor or nurse as an injection into a vein, over a period of 2 to 5 minutes. 
HALAVEN će Vam dati liječnik ili medicinska sestra injekcijom u venu tijekom 2 do 5 minuta.
Halaven is not recommended for children aged under 18 with paediatric sarcomas as it is not yet known how well it works in this age group. 
Halaven se ne preporučuje za djecu mlađu od 18 godina sa sarkomima dječje dobi jer još nije poznato koliko dobro djeluje u ovoj dobnoj skupini.
HALAVEN is for intravenous use. 
HALAVEN je za intravensku primjenu.
Management of overdose should include supportive medical interventions to treat the presenting clinical manifestations. 
Liječenje predoziranja mora uključivati potporne medikamentozne mjere, kako bi se liječile prisutne kliničke manifestacije.
The dose you will receive is based on your body surface area (expressed in squared metres, or m2) which is calculated from your weight and height. 
Doza koju ćete dobiti ovisit će o veličini površine Vašeg tijela (izraženo u kvadratnim metrima ili m2) koja se izračunava na temelju
Insomnia Depression 
Nesanica Depresija
Pharmacotherapeutic group: Other antineoplastic agents, ATC code: L01XX41 
Farmakoterapijska skupina: drugi antineoplastični lijekovi, ATK oznaka: L01XX41
HER2 Positive 
HER2-pozitivan
No in vivo data are available. 
Podaci in vivo nisu dostupni.
Nail disorder Night sweats Dry skin 
Poremećaji noktiju Noćno znojenje Suha koža Eritem
Dose reduction recommendations for retreatment are shown in the following table. 
Preporučena smanjenja doze kod ponovnog liječenja prikazana su u sljedećoj tablici.
Frequency categories are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). 
Kategorije po učestalosti definirane su na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) i vrlo rijetko (< 1/10 000).
New onset or worsening of pre-existing peripheral neuropathy has also been reported. 
Također je zabilježen nastanak ili pogoršanje postojeće periferne neuropatije.
Note: Concomitant anti-HER2 therapy was not included in Study 305 and Study 301. 
Napomena: Istodobna anti-HER2 terapija nije bila uključena u Ispitivanje 305 i Ispitivanje 301.
Treatment of Physician's Choice 
Terapija po izboru liječnika
A risk to newborns/infants cannot be excluded and therefore HALAVEN must not be used during breast-feeding (see section 4.3). 
Ne može se isključiti rizik za novorođenče i dojenče pa se stoga HALAVEN ne smije primjenjivati tijekom dojenja (vidjeti dio 4.3).
Eribulin is weakly bound to plasma proteins. 
Eribulin se slabo veže za proteine plazme.
These could be signs of an uncommon allergic reaction (may affect up to 1 in 100 people). 
To mogu biti znakovi manje česte alergijske reakcije (može se javiti u manje od 1 na 100 osoba).
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal. 
Zahtjevi za podnošenje periodičkih izvješća o neškodljivosti za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenim člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenim na europskom internetskom portalu za lijekove.
- A serious disorder of blood clotting resulting in the widespread formation of blood clots and internal bleeding. 
- ozbiljan poremećaj zgrušavanja krvi koji dovodi do opsežnog stvaranja krvnih ugrušaka i unutarnjeg krvarenja
What you need to know before you use HALAVEN 
Što morate znati prije nego počnete primjenjivati HALAVEN
In the event of extravasation, treatment should be symptomatic. 
U slučaju ekstravazacije lijeka, liječenje je simptomatsko.
There is no relevant use of HALAVEN in children and adolescents for the indication of breast cancer. 
Nema relevantne primjene lijeka HALAVEN u djece i adolescenata za indikaciju raka dojke.
Overall, the safety profiles in the breast cancer and soft tissue sarcoma patient populations were similar. 
Sveukupno, profili sigurnosti u populacije bolesnika s rakom dojke i populacije bolesnika sa sarkomom mekog tkiva su bili slični.
Eribulin is mainly (up to 70%) eliminated through biliary excretion. 
Eribulin se uglavnom (do 70%) eliminira izlučivanjem u žuč.
Patients must have progressed within 6 months of their last chemotherapeutic regimen. 
Bolesnici su morali imati progresiju bolesti unutar 6 mjeseci od zadnjeg kemoterapijskog režima.
Patients may experience nausea or vomiting. 
Bolesnici mogu osjećati mučninu ili povraćati.
In the event of an overdose, the patient should be closely monitored. 
U slučaju predoziranja bolesnika valja pomno nadzirati.
It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. 
On je strukturalno pojednostavljen sintetički analog halikondrina B, prirodne tvari izolirane iz morske spužve Halichondria okadai.